Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain

NCT05895552 is registered in ClinicalTrials.gov with Reata, a wholly owned subsidiary of Biogen as lead sponsor.

NCT NCT05895552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05895552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain
Lead sponsor
Reata, a wholly owned subsidiary of Biogen
Phase
Phase 2
Overall status
Terminated
Start date
July 28, 2023
Completion date
November 15, 2024
Enrollment
209 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathic pain